Ensembles of uncertain mathematical models can identify network response to therapeutic interventions.

The role of mechanistic modeling and systems biology in molecular medicine remains unclear. In this study, we explored whether uncertain models could be used to understand how a network responds to a therapeutic intervention. As a proof of concept, we modeled and analyzed the response of the human coagulation cascade to recombinant factor VIIa (rFVIIa) and prothrombin (fII) addition in normal and hemophilic plasma. An ensemble of parametrically uncertain human coagulation models was developed (N = 437). Each model described the time evolution of 193 proteins and protein complexes interconnected by 301 interactions under quiescent flow. The 467 unknown model parameters were estimated, using multiobjective optimization, from published in vitro coagulation studies. The model ensemble was validated using published in vitro thrombin measurements and thrombin measurements taken from coronary artery disease patients. Sensitivity analysis was then used to rank-order the importance of model parameters as a function of experimental or physiological conditions. A novel strategy for the systematic comparison of ranks identified a family of fX/FXa and fII/FIIa interactions that became more sensitive with decreasing fVIII/fIX. The fragility of these interactions was preserved following the addition of exogenous rFVIIa and fII. This suggested that exogenous rFVIIa did not alter the qualitative operation of the cascade. Rather, exogenous rFVIIa and fII took advantage of existing fluid and interfacial fX/FXa and fII/FIIa sensitivity to restore normal coagulation in low fVIII/fIX conditions. The proposed rFVIIa mechanism of action was consistent with experimental literature not used in model training. Thus, we demonstrated that an ensemble of uncertain models could unravel key facets of the mechanism of action of a focused intervention. Whereas the current study was limited to coagulation, perhaps the general strategy used could be extended to other molecular networks relevant to human health.

[1]  K. Danø,et al.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.

[2]  I. Ghareeb,et al.  Differential detection of GMSK signals with postdetection MRC over correlated and unbalanced Nakagami-m fading channels , 2005 .

[3]  R J Leipold,et al.  Mathematical Model of Serine Protease Inhibition in the Tissue Factor Pathway to Thrombin (*) , 1995, The Journal of Biological Chemistry.

[4]  K. Danø,et al.  Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.

[5]  Fania Szlam,et al.  In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry , 2009, Thrombosis and Haemostasis.

[6]  F J Doyle,et al.  Model identification of signal transduction networks from data using a state regulator problem. , 2005, Systems biology.

[7]  K. Mann,et al.  "Normal" thrombin generation. , 1999, Blood.

[8]  Kwang-Hyun Cho,et al.  Experimental Design in Systems Biology, Based on Parameter Sensitivity Analysis Using a Monte Carlo Method: A Case Study for the TNFα-Mediated NF-κ B Signal Transduction Pathway , 2003, Simul..

[9]  B. Wiman,et al.  On the kinetics of the reaction between human antiplasmin and plasmin. , 1978, European journal of biochemistry.

[10]  K. H. Lee,et al.  The statistical mechanics of complex signaling networks: nerve growth factor signaling , 2004, Physical biology.

[11]  C. Longstaff,et al.  The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1 , 2007, Journal of thrombosis and haemostasis : JTH.

[12]  N. Booth,et al.  Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI , 2003, Journal of thrombosis and haemostasis : JTH.

[13]  Giuseppe Lippi,et al.  Pharmacogenetics of vitamin K antagonists: useful or hype? , 2009, Clinical chemistry and laboratory medicine.

[14]  Dougald M Monroe,et al.  The use of recombinant factor VIIa in the treatment of bleeding disorders. , 2004, Blood.

[15]  P. Majerus,et al.  The interaction of human coagulation factor Va with platelets. , 1982, The Journal of biological chemistry.

[16]  F. Doyle,et al.  A benchmark for methods in reverse engineering and model discrimination: problem formulation and solutions. , 2004, Genome research.

[17]  S. Diamond,et al.  Systems biology to predict blood function , 2009, Journal of thrombosis and haemostasis : JTH.

[18]  A. Fogelson,et al.  Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. , 2001, Biophysical journal.

[19]  Julia Mitchell,et al.  Haemophilia and inhibitors. 1: Diagnosis and treatment. , 2008, Nursing times.

[20]  P. Perrotta,et al.  Platelet activation in a circulating flow loop: combined effects of shear stress and exposure time , 2003, Platelets.

[21]  J. Arnold,et al.  An ensemble method for identifying regulatory circuits with special reference to the qa gene cluster of Neurospora crassa , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Dougald M Monroe,et al.  Manipulation of prothrombin concentration improves response to high‐dose factor VIIa in a cell‐based model of haemophilia , 2006, British journal of haematology.

[23]  Y. Nakatomi,et al.  A novel therapeutic approach combining human plasma‐derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone , 2003, Vox sanguinis.

[24]  Eduardo Sontag,et al.  Untangling the wires: A strategy to trace functional interactions in signaling and gene networks , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Atsma,et al.  Development of a new test for the global fibrinolytic capacity in whole blood , 2007, Journal of thrombosis and haemostasis : JTH.

[26]  K Kolev,et al.  Regulation of fibrinolytic activity of neutrophil leukocyte elastase, plasmin, and miniplasmin by plasma protease inhibitors. , 1994, The Journal of biological chemistry.

[27]  Y Komiyama,et al.  Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. , 1990, Biochemistry.

[28]  James H Morrissey,et al.  Polyphosphate modulates blood coagulation and fibrinolysis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G Pohl,et al.  Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. , 1994, Biochimica et biophysica acta.

[30]  Christopher R. Myers,et al.  Universally Sloppy Parameter Sensitivities in Systems Biology Models , 2007, PLoS Comput. Biol..

[31]  A. Shapiro,et al.  Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. , 2008, Clinical advances in hematology & oncology : H&O.

[32]  David R. Corey,et al.  Substrate Specificity of Tissue Type Plasminogen Activator , 1995, The Journal of Biological Chemistry.

[33]  M. Schenone,et al.  The blood coagulation cascade , 2004, Current opinion in hematology.

[34]  J. Oliver,et al.  Platelet activity of high‐dose factor VIIa is independent of tissue factor , 1997, British journal of haematology.

[35]  Kazuo Fujikawa,et al.  Historical perspective of factor XI. , 2005, Thrombosis research.

[36]  Martin Zenker,et al.  Influence of soluble fibrin on reaction kinetics of plasmin type 1 and type 2 with α2-antiplasmin , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[37]  S W Hall,et al.  Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. , 1991, The Journal of biological chemistry.

[38]  J. Badimón,et al.  Blood-borne tissue factor: another view of thrombosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Boffa,et al.  Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties* , 1998, The Journal of Biological Chemistry.

[40]  H. Kitano A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[41]  S. Thorsen,et al.  Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. , 1988, European journal of biochemistry.

[42]  J. Bailey Complex biology with no parameters , 2001, Nature Biotechnology.

[43]  Kumbakonam R. Rajagopal,et al.  A Model Incorporating Some of the Mechanical and Biochemical Factors Underlying Clot Formation and Dissolution in Flowing Blood , 2003 .

[44]  K. Mann,et al.  A model for the tissue factor pathway to thrombin. II. A mathematical simulation. , 1994, The Journal of biological chemistry.

[45]  Shapiro,et al.  A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors , 1998 .

[46]  M. Nesheim,et al.  A Study of the Protection of Plasmin from Antiplasmin Inhibition within an Intact Fibrin Clot during the Course of Clot Lysis* , 2004, Journal of Biological Chemistry.

[47]  K. Mann,et al.  Mechanism of factor VIIa-dependent coagulation in hemophilia blood. , 2002, Blood.

[48]  Christopher R. Myers,et al.  Optimal experimental design in an EGFR signaling and down-regulation model , 2006, q-bio/0610024.

[49]  D. Siegel,et al.  Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. , 1988, The American journal of medicine.

[50]  Joseph M. Scandura,et al.  Structural and Functional Characterization of Platelet Receptor-mediated Factor VIII Binding* , 2000, The Journal of Biological Chemistry.

[51]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[52]  L. Sottrup-jensen,et al.  Stopped-flow fluorescence kinetics of bovine alpha 2-antiplasmin inhibition of bovine midiplasmin. , 1995, The Biochemical journal.

[53]  F B Taylor,et al.  Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model , 1993, Infection and immunity.

[54]  Kenichi A Tanaka,et al.  Blood Coagulation: Hemostasis and Thrombin Regulation , 2009, Anesthesia and analgesia.

[55]  M. Nesheim,et al.  Activated Thrombin-activatable Fibrinolysis Inhibitor Reduces the Ability of High Molecular Weight Fibrin Degradation Products to Protect Plasmin from Antiplasmin* , 2004, Journal of Biological Chemistry.

[56]  K. Mann,et al.  Thrombin functions during tissue factor-induced blood coagulation. , 2002, Blood.

[57]  Celia Arnaud DRIVING A SPIKE INTO VIRUSES , 2006 .

[58]  Zhiliang Xu,et al.  A multiscale model of thrombus development , 2008, Journal of The Royal Society Interface.

[59]  David Garcia,et al.  Novel anticoagulants and the future of anticoagulation. , 2009, Thrombosis research.

[60]  K Fujikawa,et al.  Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. , 1991, The Journal of biological chemistry.

[61]  G. Hansson Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[62]  G. Müller‐Berghaus,et al.  Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[63]  D. Loskutoff,et al.  Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease , 2005, Thrombosis and Haemostasis.

[64]  Stefan Roth,et al.  Covariance Matrix Adaptation for Multi-objective Optimization , 2007, Evolutionary Computation.

[65]  Celia Arnaud Systems biology's clinical future , 2006 .

[66]  Anne Dell,et al.  Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-antiplasmin. , 2002, Thrombosis research.

[67]  G. Young,et al.  Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[68]  C. Kessler,et al.  Newer concepts of blood coagulation , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[69]  Eduardo D. Sontag,et al.  Inferring dynamic architecture of cellular networks using time series of gene expression, protein and metabolite data , 2004, Bioinform..

[70]  Kenneth G. Mann,et al.  Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation , 1997, The Journal of Biological Chemistry.

[71]  K. C. Jones,et al.  A Model for the Stoichiometric Regulation of Blood Coagulation* , 2002, The Journal of Biological Chemistry.

[72]  P. Walsh,et al.  Platelet receptor occupancy with factor IXa promotes factor X activation. , 1989, The Journal of biological chemistry.

[73]  F. Allgöwer,et al.  Robustness properties of apoptosis models with respect to parameter variations and intrinsic noise. , 2005, Systems biology.

[74]  H. Roberts,et al.  Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[75]  K. Rajagopal,et al.  A Model for the Formation and Lysis of Blood Clots , 2006, Pathophysiology of Haemostasis and Thrombosis.

[76]  Kenneth G. Mann,et al.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes , 1990 .

[77]  J. Deinum,et al.  The Importance of Enzyme Inhibition Kinetics for the Effect of Thrombin Inhibitors in a Rat Model of Arterial Thrombosis , 1997, Thrombosis and Haemostasis.

[78]  Michael R Pinsky,et al.  Current Evidence Based Guidelines for Factor VIIa Use in Trauma: The Good, the Bad, and the Ugly , 2008, The American surgeon.

[79]  M. Rånby,et al.  Studies on the kinetics of plasminogen activation by tissue plasminogen activator. , 1982, Biochimica et biophysica acta.

[80]  J. Stelling,et al.  Robustness properties of circadian clock architectures. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[81]  Fania Szlam,et al.  Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan , 2005, Thrombosis and Haemostasis.

[82]  A D Shapiro,et al.  Recombinant Factor VIIa in the Treatment of Bleeding in Hemophilic Children with Inhibitors , 2000, Seminars in thrombosis and hemostasis.

[83]  K. S. Brown,et al.  Optimal experimental design in an epidermal growth factor receptor signalling and down-regulation model. , 2007, IET systems biology.

[84]  P. Carmeliet,et al.  Clotting Factors Build Blood Vessels , 2001, Science.

[85]  S. Olson,et al.  Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. , 1992, The Journal of biological chemistry.

[86]  K. Mann,et al.  Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. , 1993, The Journal of biological chemistry.

[87]  Deyan Luan,et al.  Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies , 2007, PLoS Comput. Biol..

[88]  S. Coughlin,et al.  How the protease thrombin talks to cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[89]  C. Danforth,et al.  The impact of uncertainty in a blood coagulation model. , 2009, Mathematical medicine and biology : a journal of the IMA.

[90]  H. Hemker,et al.  Factor XI–Dependent Reciprocal Thrombin Generation Consolidates Blood Coagulation when Tissue Factor Is Not Available , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[91]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.

[92]  J. Maraganore,et al.  Kinetic mechanism for the interaction of Hirulog with thrombin. , 1994, Biochemistry.

[93]  J. Griffin,et al.  Purification and characterization of plasma protein C inhibitor. , 1989, Thrombosis research.

[94]  U. Hedner,et al.  Factor VIIa and its potential therapeutic use in bleeding-associated pathologies , 2008, Thrombosis and Haemostasis.

[95]  Chiara Dall’Asta,et al.  Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review , 2009, Internal and emergency medicine.

[96]  A D Shapiro,et al.  Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.

[97]  L. You,et al.  Evolutionary design on a budget: robustness and optimality of bacteriophage T7. , 2006, Systems biology.

[98]  Peter J. Fleming,et al.  An Overview of Evolutionary Algorithms in Multiobjective Optimization , 1995, Evolutionary Computation.

[99]  C. Esmon,et al.  The roles of protein C and thrombomodulin in the regulation of blood coagulation. , 1984, The Journal of biological chemistry.

[100]  J. Varner,et al.  A Test of Highly Optimized Tolerance Reveals Fragile Cell-Cycle Mechanisms Are Molecular Targets in Clinical Cancer Trials , 2008, PloS one.

[101]  M. A. Payne,et al.  Effect of soluble tissue factor on the kinetic mechanism of factor VIIa: enhancement of p-guanidinobenzoate substrate hydrolysis. , 1996, Biochemistry.

[102]  D. Sinha,et al.  Functional characterization of platelet-bound factor XIa: retention of factor XIa activity on the platelet surface. , 1986, Blood.

[103]  H. Kitano,et al.  Computational systems biology , 2002, Nature.

[104]  Dougald M Monroe,et al.  A cell-based model of thrombin generation. , 2006, Seminars in thrombosis and hemostasis.

[105]  James F. Antaki,et al.  Computational Simulation of Platelet Deposition and Activation: I. Model Development and Properties , 1999, Annals of Biomedical Engineering.

[106]  Kwang-Hyun Cho,et al.  Dynamics of biological systems: role of systems biology in medical research , 2006, Expert review of molecular diagnostics.

[107]  H. Tien,et al.  The use of recombinant factor VIIa in trauma patients. , 2009, The Journal of the American Academy of Orthopaedic Surgeons.

[108]  K. Mann,et al.  Biochemistry and Physiology of Blood Coagulation , 1999, Thrombosis and Haemostasis.

[109]  P. A. von dem Borne,et al.  Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. , 1995, Blood.

[110]  S. Béguin,et al.  The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability , 2002, Pathophysiology of Haemostasis and Thrombosis.

[111]  Pål Aukrust,et al.  Early anti-thrombotic and anti-inflammatory actions of statins and fibrates – time for adjuvant therapy in acute coronary syndromes? , 2005, Thrombosis and Haemostasis.

[112]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[113]  Alisa S Wolberg,et al.  A Variant of Recombinant Factor VIIa With Enhanced Procoagulant and Antifibrinolytic Activities in an In Vitro Model of Hemophilia , 2007, Arteriosclerosis, thrombosis, and vascular biology.